Nasdaq Delisting Looms for Trinity Biotech After MVPHS Deadline Miss
TRIB sits 21% above its 52-week low of $7.94 on light trading volume (0.1× avg).
Summary
Trinity Biotech received a Nasdaq delisting determination after failing to meet the $15 million MVPHS requirement by the August 18, 2026 deadline. The company will request a hearing to stay suspension and seek an extension up to February 24, 2027.
Key Events · Legal and Risk Events · TRIB
-
Nasdaq Delisting Determination Received
On August 28, 2026, Trinity Biotech received a staff determination letter from Nasdaq confirming it failed to regain compliance with the $15 million MVPHS requirement by the August 18, 2026 deadline.
-
Hearing Request to Stay Delisting
The company intends to timely request a hearing before the Nasdaq Hearings Panel, which would automatically stay any suspension or delisting action pending the hearing and any extension period granted by the Panel (up to February 24, 2027).
-
Strategic Transactions to Boost MVPHS
Management states it has initiatives and strategic transactions at advanced stages that, if completed, would be expected to increase MVPHS above the $15 million minimum, but there is no assurance of success.
-
Operational Transformation Progress
Completed manufacture of approximately 9 million TrinScreen HIV tests under the outsourced model and commenced Uni-Gold HIV outsourced manufacturing; upgraded HbA1c column system rolled out in three largest international markets.
Analysis · TRIB · Life Sciences
A Nasdaq staff determination letter dated August 28, 2026, confirmed that Trinity Biotech failed to regain compliance with the $15 million minimum market value of publicly held shares (MVPHS) requirement by the August 18, 2026 deadline. The company plans to request a hearing before the Nasdaq Hearings Panel, which would automatically stay any suspension or delisting action pending the hearing and any extension period granted by the Panel (up to February 24, 2027). This is a critical governance and listing risk event — delisting would severely impair liquidity and investor access. The company states it has strategic transactions at advanced stages that could increase MVPHS above $15 million, but there is no assurance the Panel will grant an extension or that compliance will be regained. Against the backdrop of a 1-for-30 reverse split in July 2026 and a $4.35 million ATM offering in June 2026, this delisting notice compounds existing distress signals.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRIB was trading at $9.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $7.94 to $52.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.